Vol 15, No 2 (2019)
Case report
Published online: 2019-05-17
Page views 930
Article views/downloads 532
Get Citation

Connect on Social Media

Connect on Social Media

Complete pathological remission after palliative therapy with sorafenib in hepatocellular carcinoma — case report

Aneta Lebiedzińska12, Dawid Sigorski1, Maciej Michalak3, Zygmunt Kozielec4, Anna Doboszyńska2, Dariusz Zadrożny5, Paweł Różanowski1
Oncol Clin Pract 2019;15(2):127-131.

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary malignant liver cancer. The five-year overall survival (OS) in men diagnosed with HCC does not exceed 9%. Patients (pts) with advanced disease are treated with sorafenib (multikinase inhibitor). In randomised trials the OS advantage was within the range of three months for sorafenib. Stabilisation of disease was achieved in 71% of patients, and no case of CR was reported. We present a case of 60-year-old patient with locally advanced cT3aN0M0 (stage IIIA according to seventh TNM) bifocal HCC (12 × 10 cm and 10 × 8 cm). The diagnosis was confirmed by pathologic examination. Due to the clinical stage, palliative treatment with sorafenib was administered from January 2016 to February 2017. A clinical partial response (cPR) enabled surgery. In May 2017, left-sided liver bisegmentomy and resection of residual lesion in segment 6 were performed. The pathological report revealed ypCR. Subsequently, pathology verification changed the primary diagnosis to PR. In September 2017 thermoablation of lesion in segment 5 of the liver was performed. The increased AFP (alpha-fetoprotein) level at baseline was normalised during treatment. The sorafenib therapy was completed after one year. The patient remains in follow-up with no evidence of relapse. Treatment with sorafenib in the presented case enabled radical therapy, so the palliative treatment turned out to be an induction treatment. Clinical CR (especially pCR) in advanced non-operable solid tumours after systemic treatment is quite rare (3–15%), and even less common in HCC. So far, only a few cases of achievement of CR during sorafenib therapy in HCC have been described.

Article available in PDF format

Purchase Subscription

References

  1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27(9): 1485–1491.
  2. Małkowski P, Pacholczyk M, Łagiewska B, et al. Rak wątrobowokomórkowy — epidemiologia i leczenie. Przegl Epidemiol. 2006; 60: 731–740.
  3. Krawczyk M. Rak wątrobowo-komórkowy. Medical Science Review — Hepatologia. 2008; 8: 92–99.
  4. Bosch F, Ribes J, Díaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004; 127(5): S5–S16.
  5. Sant M, Allemani C, Santaquilani M, et al. EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009; 45(6): 931–991.
  6. Te Sligte K, Bourass I, Sels JP, et al. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med. 2004; 15(1): 10–21.
  7. Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 2009; 50(2): 351–357.
  8. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97(20): 1532–1538.
  9. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378–390.
  10. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25–34.
  11. Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo. 2018; 11(3): 185–192.
  12. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013; 31(32): 4067–4075.
  13. Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015; 33(6): 559–566.
  14. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014; 312(1): 57–67.
  15. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31(28): 3517–3524.
  16. Bruix J, Qin S, Merle P, et al. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10064): 56–66.
  17. Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018; 48(6): 598–609.
  18. Sacco R, Granito A, Bargellini I, et al. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol. 2018 [Epub ahead of print].
  19. Bruix J, Takayama T, Mazzaferro V, et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16(13): 1344–1354.
  20. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088): 2492–2502.
  21. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017; 66(3): 545–551.
  22. Hampton T. Gut microbes may shape response to cancer immunotherapy. JAMA. 2018; 319(5): 430–431.